Jonathan Roy Vice President of Pharma Partnerships, Jon is leading Companion Diagnostic development for Leica Biosystems. He has spent the last 10 years focused on companion diagnostic development and implementation globally both at Leica and as Head of Commercial Strategy for Companion Diagnostics at GlaxoSmithKline.
Current technology allows tumors to be painted with multiple colors, termed multiplex staining. Multiplex staining today used in research, may also assist with cancer diagnoses clinically via: preservation of tissue, improved diagnostic accuracy, and enhanced diagnostic insight.
